micro-community-banner
 
  • Saved

3yr
Type 2 Diabetes and Obesity

Obesity is an important risk factor for type 2 diabetes.1 Both obesity and type 2 diabetes are risk factors for cardiovascular disease.2 Weight management is a key part of the recommended care for patients with type 2 diabetes.3 Lifestyle interventions (diet and exercise) are the cornerstone of management but are not effective for all patients and other interventions, including pharmacotherapy are often required.4 However, approved drug treatments for type 2 diabetes can have positive and negative effects on patients’ weight.5




  • What challenges do you face when trying to achieve weight loss in your patients who have type 2 diabetes?

  • Which drugs treatments indicated for type 2 diabetes are most suitable for patients who are overweight or obese and why?



 



References:




  1. Cameron et al. Quantifying the Sex-Race/Ethnicity-Specific Burden of Obesity on Incident Diabetes Mellitus in the United States, 2001 to 2016: MESA and NHANES. Journal of the American Heart Association. 2021 Feb 16;10(4):e018799.

  2. Scherer and Hill. Obesity, Diabetes, and Cardiovascular Diseases: A Compendium. Circulation Research. 2016 May 27; 118(11): 1703–1705.

  3. Davies et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018; 61:2461–2498.

  4. Leitner et al. Obesity and Type 2 Diabetes: Two Diseases with a Need for Combined Treatment Strategies - EASO Can Lead the Way. Obesity Facts. 2017 Nov; 10(5): 483–492.

  5. Apovian et al. Body Weight Considerations in the Management of Type 2 Diabetes. Advances in Therapy. 2019; 36(1): 44–58.


  • 3yr
    Lifestyle modification is pretty challenging as we all know we are a society with fast food restaurants around us and we refuse to be active and engage in daily exercise. Show More
  • 3yr
    What other drugs taken in addition to antidiabetic agents lead to weight gain (e.g., antidepressants)? How do you manage weight concerns in such patients?

Show More Comments

  • Saved

3yr
Type 2 Diabetes and Obesity

Obesity is an important risk factor for type 2 diabetes.1 Both obesity and type 2 diabetes are risk factors for cardiovascular disease.2 Weight management is a key part of the recommended care for patients with type 2 diabetes.3 Lifestyle interventions (diet and exercise) are the cornerstone of management but are not effective for all patients and other interventions, including pharmacotherapy are often required.4 However, approved drug treatments for type 2 diabetes can have positive and negative effects on patients’ weight.5




  • What challenges do you face when trying to achieve weight loss in your patients who have type 2 diabetes?

  • Which drugs treatments indicated for type 2 diabetes are most suitable for patients who are overweight or obese and why?



 



References:




  1. Cameron et al. Quantifying the Sex-Race/Ethnicity-Specific Burden of Obesity on Incident Diabetes Mellitus in the United States, 2001 to 2016: MESA and NHANES. Journal of the American Heart Association. 2021 Feb 16;10(4):e018799.

  2. Scherer and Hill. Obesity, Diabetes, and Cardiovascular Diseases: A Compendium. Circulation Research. 2016 May 27; 118(11): 1703–1705.

  3. Davies et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018; 61:2461–2498.

  4. Leitner et al. Obesity and Type 2 Diabetes: Two Diseases with a Need for Combined Treatment Strategies - EASO Can Lead the Way. Obesity Facts. 2017 Nov; 10(5): 483–492.

  5. Apovian et al. Body Weight Considerations in the Management of Type 2 Diabetes. Advances in Therapy. 2019; 36(1): 44–58.


  • 3yr
    Lifestyle modification is pretty challenging as we all know we are a society with fast food restaurants around us and we refuse to be active and engage in daily exercise. Show More
  • 3yr
    What other drugs taken in addition to antidiabetic agents lead to weight gain (e.g., antidepressants)? How do you manage weight concerns in such patients?

Show More Comments

  • Saved

3yr
A real-world study on SGLT2 inhibitors and diabetic kidney disease progression

A real-world study on SGLT2 inhibitors and diabetic kidney disease progression

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217649/

Allen Yan Lun Liu, Serena Low, Ester Yeoh, Eng Kuang Lim, Claude Jeffrey Renaud, Selene Tse Yen Teoh, Grace Feng Ling Tan, Chung Cheen Chai, Bo Liu, Tavintharan Subramaniam, Chee...



Conclusions: This real-world study demonstrates the benefits of SGLT2is on CKD progression and ESKD. The effect is more pronounced in moderate to advanced CKD patients.

  • Saved

3yr
Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents

Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents

Source : https://www.sciencedirect.com/science/article/pii/S2001037022002136?via=ihub

Repositioning or repurposing drugs account for a substantial part of entering approval pipeline drugs, which indicates that drug repositioning has huge market potential and value. Computational technologies such as machine...



Conclusion/Relevance: In this review, we focus on the machine learning methods for the development of new T2DM drugs and give an overview of the repurposing potential of the existing antidiabetic agents.


  • Saved

3yr
Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis

Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis

Source : https://www.sciencedirect.com/science/article/abs/pii/S1871402122001539?via=ihub

Weekly low dose semaglutide is effective in reducing alanine aminotransferase (ALT). * This beneficial impact of injectable semaglutide is seen in people with or without type-2 diabetes. * Numbers of...



Conclusion: This meta-analysis provides reassuring data on efficacy of low dose semaglutide injections in improving ALT and certain radiologic features in MAFLD. Current conclusions are limited by small number of patients evaluated. Urgent need remains for larger studies focussing on liver biopsy.


  • 3yr
    Semaglutide mg weekly is effective in improving ALT and other components of metabolic syndrome
  • 3yr
    Key Points • Source: Cardiovascular Diabetology • Conclusions: “This meta-analysis provides reassuring data on efficacy of low dose semaglutide injections in improving ALT and certain radiologic features in MAFLD [metabolic-dysfunction associated fatty-liver disease]. Current Show More